Promedior,
Inc., a clinical stage biotechnology company developing novel biologic
therapeutics for the treatment of fibrosis, announced today that
biopharmaceutical industry veteran William Hodder has joined the company
as Vice President of Business Development. Mr. Hodder will be
responsible for leading the Promedior’s business development activities
as its lead drug candidates targeting fibrosis continue to advance
through clinical development for serious and life threatening fibrotic
diseases, including myelofibrosis and idiopathic pulmonary fibrosis
(IPF).
"We are pleased to welcome William Hodder to Promedior’s senior
management team," said Suzanne L. Bruhn, PhD, President and Chief
Executive Officer of Promedior. “Mr. Hodder’s strong experience in the
biotechnology industry and specifically within the field of fibrotic
diseases is a perfect fit for our needs as we continue to deepen and
broaden the clinical data from our ongoing programs and consider
partnerships for the next stage of our growth.”
Mr. Hodder brings to Promedior more than 25 years of pharmaceutical and
biotechnology industry experience. Prior to joining Promedior, Mr.
Hodder was founder and CEO of Trenovus, Inc. a start-up biotechnology
company focused on developing novel inhibitors of heterotopic
ossification. Prior to Trenovus, Mr. Hodder was Vice President, Business
Development of FibroGen, Inc., where he was responsible for all
licensing and M&A activity. Significantly, Mr. Hodder led FibroGen in
the historic out-licensing of HIF prolyl hydroxylase inhibitors for
anemia indications to Astellas for the European, South Africa and Middle
East territories. Prior to joining FibroGen, he served as Director of
Business Development and Marketing at drug delivery company Aradigm and
held sales, marketing, and product development positions at Penederm,
Ciba Geigy, Bristol-Myers Squibb Company, and Marion Laboratories. Mr.
Hodder completed his undergraduate studies at Oakland University with a
B.S. in biology and holds an M.B.A. from the University of Chicago Booth
School of Business.
“I am excited to join Promedior and look forward to forging the key
business alliances that will build on the strength of the company’s
clinical data to help to drive the company’s growth,” said William
Hodder, Vice President of Business Development for Promedior. “It is a
privilege to work with a group so committed to delivering new
therapeutic options for fibrotic diseases to physicians and patients.”
About Promedior
Promedior
is a clinical stage biotechnology company pioneering the development of
targeted therapeutics to treat diseases involving fibrosis. Fibrosis is
a harmful process that occurs in many diseases, when normal healthy
tissue is replaced with excessive scar tissue, compromising function and
ultimately leading to organ failure. Promedior's proprietary platform is
based upon Pentraxin-2, an endogenous human protein that is specifically
active at the site of tissue damage and works as an agonist, preventing
and potentially reversing fibrosis.
Promedior has successfully advanced its lead therapeutic candidate in
human clinical trials, and is initially focused on rare fibrotic
diseases, including idiopathic pulmonary fibrosis (IPF) and
myelofibrosis. Promedior is backed by leading global healthcare venture
investors, has a significant intellectual property estate relating to
the discoveries and applications of Pentraxin-2 therapeutics and is led
by an experienced management team. For additional information about
Promedior, please visit www.promedior.com.
Copyright Business Wire 2014